NUMBRINO Drug Patent Profile
✉ Email this page to a colleague
When do Numbrino patents expire, and when can generic versions of Numbrino launch?
Numbrino is a drug marketed by Cody Labs Inc and is included in one NDA.
The generic ingredient in NUMBRINO is cocaine hydrochloride. There are three drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the cocaine hydrochloride profile page.
Summary for NUMBRINO
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for NUMBRINO |
| What excipients (inactive ingredients) are in NUMBRINO? | NUMBRINO excipients list |
| DailyMed Link: | NUMBRINO at DailyMed |
DrugPatentWatch® Estimated Generic Entry Opportunity Date for NUMBRINO
Generic Entry Date for NUMBRINO*:
Constraining patent/regulatory exclusivity:
NEW PRODUCT NDA:
Dosage:
SOLUTION;NASAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Anatomical Therapeutic Chemical (ATC) Classes for NUMBRINO
US Patents and Regulatory Information for NUMBRINO
NUMBRINO is protected by zero US patents and two FDA Regulatory Exclusivities.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of NUMBRINO is See Plans and Pricing.
This potential generic entry date is based on NEW PRODUCT.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
FDA Regulatory Exclusivity protecting NUMBRINO
NEW PRODUCT
Exclusivity Expiration: See Plans and Pricing
NEW CHEMICAL ENTITY
Exclusivity Expiration: See Plans and Pricing
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cody Labs Inc | NUMBRINO | cocaine hydrochloride | SOLUTION;NASAL | 209575-001 | Jan 10, 2020 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | See Plans and Pricing | ||||
| Cody Labs Inc | NUMBRINO | cocaine hydrochloride | SOLUTION;NASAL | 209575-001 | Jan 10, 2020 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | See Plans and Pricing | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
